Pelabresib
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Malignancy
Conditions
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Trial Timeline
Aug 13, 2024 → Jun 30, 2027
NCT ID
NCT06401356About Pelabresib
Pelabresib is a phase 3 stage product being developed by Novartis for Hematologic Malignancy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06401356. Target conditions include Hematologic Malignancy, Solid Tumor, Advanced Malignancies.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07422610 | Phase 1 | Recruiting |
| NCT06401356 | Phase 3 | Recruiting |
Competing Products
20 competing products in Hematologic Malignancy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| RLYB116 for Injection | Rallybio | Phase 1 | 25 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 41 |
| Isavuconazole | Astellas Pharma | Phase 2 | 52 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 33 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 33 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 33 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 33 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 33 |
| ABBV-101 | AbbVie | Phase 1 | 33 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 52 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 33 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 41 |
| ridaforolimus | Merck | Phase 2 | 52 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 2 | 52 |
| ARQ 621 | Merck | Phase 1 | 33 |
| Nemtabrutinib | Merck | Phase 1 | 33 |